Maintenance Treatment With S-1 in Gastric Cancer Patients

Inclusion Criteria

• •Age older than 18 years
• •Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1
• •At least one measurable lesion according to the Response Evaluation Criteria in Solid Tumor (RECIST version 1.0)
• •Histologically confirmed gastric cancer with inoperable locally advanced or recurrent and/or metastatic disease, not amenable to curative therapy
• •No previous chemotherapy for metastatic GC was allowed, the interval after the end of adjuvant/neoadjuvant chemotherapy beyond 6 months was allowable
• •Life expectancy of at least 3 months
• •Adequate hematologic, hepatic and renal function. Neutrophil count ≥ 1.5 × 109/L; platelet count ≥ 100 × 109/L; Serum bilirubin ≤ 1.5 × upper limit of normal (ULN), AST or ALT ≤ 2.5 × ULN (or ≤ 5 × ULN in patients with liver metastases), alkaline phosphatase ≤ 2.5 × ULN (or ≤ 5 × ULN in patients with liver metastases, or ≤ 10 × ULN in patients with bone but no liver metastases); serum creatinine ≤ 1.5 × ULN；and albumin ≥ 25 g/L
• •Patients who achieved objective response or stable disease after 2-6 month first-line chemotherapy
• •The first-line chemotherapy regimens were doublets including platinum (cisplatin or oxaliplatin) plus fluoropyrimidine (5-FU, capecitabine, or S-1)
• •Signed informed consent